Other substances

C135

A human anti-SARS-CoV-2 monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

C135 is a monoclonal antibody identified in serum of a COVID-19 convalescent patient. It experimentally neutralized SARS-CoV-2 live virus in vitro (Robbiani et al., 2020).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 Spike protein Spike variant Protein factor In vitro Antibody Mixed substance	Vero E6 cells; patient sera; SARS-CoV-2 live virus (WA1, B.1.1.7, and B.1.351 strains); (VSV) SARS-CoV-2 Spike pseudoviruses (various strain/mutations)	49.96	The antibody retains its activity against the B.1.351 strain in vitro.	Mar/08/2021
Convergent antibody responses to SARS-CoV-2 in convalescent individuals Spike protein Novel compound Biophysical assay Protein factor In vitro Mechanism Antibody	VeroE6 cells; SARS-CoV-2 (USA-WA1/2020); patient sera	49.96	The antibody experimentally neutralized SARS-CoV-2 live virus in vitro with an IC50 of 2.98 ng/ml.	Jun/18/2020

AI-suggested references

Link	Publication date
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice	Sep/15/2021
Energy landscape of the SARS-CoV-2 reveals extensive conformational heterogeneity	Nov/12/2020
Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies	Mar/30/2020
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques	Jul/06/2021

Export (.csv)